Drug Profile
Erythropoietin receptor agonist - Biocad
Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Biocad
- Developer Ligand Pharmaceuticals
- Class Antihaemorrhagics
- Mechanism of Action Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological disorders
Most Recent Events
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 28 Mar 2021 No recent reports of development identified for phase-I development in Haematological-disorders in Unknown
- 28 Feb 2018 Phase-I clinical trials in Haematological disorders (Ligand Pharmaceuticals pipeline, April 2018)